Evidence map›Paper›PMID 31077235›Full record

ArticleRadiation oncology (London, England)2019

Increased heat shock protein 70 (Hsp70) serum levels and low NK cell counts after radiotherapy - potential markers for predicting breast cancer recurrence?

Anna Rothammer, Eva K Sage, Caroline Werner, Stephanie E Combs, Gabriele Multhoff

Open access · goldAbstract read
In one paragraph

Article in Radiation oncology (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Heat Shock Proteins and Breast Cancer.International journal of molecular sciences · 2024
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Anna RothammerCenter for Translational Cancer research (TranslaTUM), Radiation Immuno-Oncology Group, Technical University of Munich (TUM), School of Medicine, Klinikum rechts der Isar, Einsteinstr. 25, 81675, Munich, Germany.
Eva K SageDepartment of Radiation Oncology, Technical University of Munich (TUM), School of Medicine, Klinikum rechts der Isar TUM, Munich, Germany.
Caroline WernerCenter for Translational Cancer research (TranslaTUM), Radiation Immuno-Oncology Group, Technical University of Munich (TUM), School of Medicine, Klinikum rechts der Isar, Einsteinstr. 25, 81675, Munich, Germany.
Stephanie E CombsDepartment of Radiation Oncology, Technical University of Munich (TUM), School of Medicine, Klinikum rechts der Isar TUM, Munich, Germany.
Gabriele MulthoffCenter for Translational Cancer research (TranslaTUM), Radiation Immuno-Oncology Group, Technical University of Munich (TUM), School of Medicine, Klinikum rechts der Isar, Einsteinstr. 25, 81675, Munich, Germany. Gabriele.multhoff@tum.de.
Klinikum rechts der Isar · DE

Funding

BMBF 01GU823BMBF 02NUK038ABMWI ZF4320102CS7BMWI ZF4320104AJ8Deutsche Forschungsgemeinschaft SFB824/3Deutsche Forschungsgemeinschaft STA1520/1-1
6 · The paper itself

Abstract

backgroundBreast cancer is the most common invasive tumor in women worldwide and the second cause of cancer-related deaths. After breast conserving surgery the tumor bed gets irradiated. Radiation-induced tumor cell death has been found to be associated with the release of damage-associated molecular patterns (DAMPs) including free Hsp70 that can stimulate inflammatory immune responses. Therefore, Hsp70 serum levels as well as the composition of lymphocyte subpopulations have been measured in breast cancer patients during therapy and in the follow-up period as potential predictors for clinical outcome.

methodsThe serum of 40 breast cancer patients, who received a breast-conserving surgery and adjuvant radiotherapy (RT) was examined for soluble, free Hsp70 using the R&D Human HSP70 DuoSet and lipHsp70 ELISA. Lymphocyte subpopulations and total lymphocyte counts were analysed by multiparameter flow cytometry in the peripheral blood. Blood samples were collected before (t1), after 30 Gy (t2) and 60 Gy (t3), 6 weeks (t4), 6 months (t5) and 1 year (t6) after RT. Clinical responses were assessed regularly up to 5 years after RT.

resultsPatients who developed a contralateral recurrence or metastases within the first 2 years after RT had significantly higher serum Hsp70 values at the end of RT (t3; p = 0.03) up to 6 weeks after RT (t4; p = 0.007) compared to patients who either remained disease-free or developed a secondary endometrial carcinoma. Clinicopathological parameters such as age, tumor size, grading and TNM-stage of the resected tumors, adjuvant chemotherapy and irradiation dose did not affect serum Hsp70 levels. Elevated free Hsp70 levels might be indicative for a chronic inflammatory response which could support tumor recurrence. Lymphocyte subpopulation analysis revealed lower NK cell counts after RT in recurrence/metastases patients as compared to disease-free patients. In contrast, no significant changes were observed in the proportion of T and B cells.

conclusionLongitudinal elevated serum levels of free Hsp70 up to 6 weeks after RT and dropping NK cell counts might be predictive for an unfavourable prognosis in patients with breast cancer.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsFemaleHSP70 Heat-Shock ProteinsHumansKiller Cells, NaturalMiddle AgedNeoplasm Recurrence, LocalPrognosisRadiotherapy, AdjuvantBiomarkers, TumorHSP70 Heat-Shock ProteinsHspa14 protein, humanBreast carcinoma predictionDAMPsFree Hsp70ImmunophenotypingRadiotherapy

Identifiers

PMID31077235
PMCPMC6509784
OpenAlexW2947249053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.